Korro Bio’s (KRRO) treatment of alpha-1 antitrypsin deficiency received FDA orphan designation, according to a post on the agency’s stie.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: